BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BG Medicine (BGMD) Pulls FDA 510(k) Submission for CardioScore Test


8/10/2012 8:33:42 AM

Boston Business Journal by Julie M. Donnelly, Reporter

BG Medicine, Inc. (BGMD), the maker of an FDA-approved diagnostic test for heart failure, saw its shares fall almost 6 percent Thursday. This followed the company reporting that its second quarter loss widened on increased costs, and the company withdrew a diagnostic test from FDA consideration .

The Waltham, Mass-based diagnostics company reported a net loss of $6.4 million in the most recent quarter, compared with a loss of $4.8 million for the quarter ended June 30, 2011. Revenues for the second quarter were $622,000, up from $221,000 in the corresponding period last year.

Selling, general and administrative expenses for the quarter ended June 30, 2012 increased to $4.3 million from $2.5 million during the same quarter ended June 30, 2011. Marketing expenses increased $701,000, due to marketing activities and other costs associated with commercialization support for the BGM Galectin-3 test, which has already been approved by the FDA. General and administrative expenses increased $1.1 million primarily due to personnel-related costs, the company said..

BG Medicine said it has been in continuing discussions with the FDA over the approval process for its CardioScore test, after the regulatory agency said it needed confirmation of certain data obtained through medical insurance claims. The company disclosed in its earnings report that it would not be able to meet the FDA’s August 15 deadline to provide the additional information, and withdrew the application for approval. The company plans to re-submit the application when it has all necessary documentation.

BG Medicine’;s stock was trading at $6.50 on Thursday afternoon, down from $6.90 at the previous close.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES